基于网络药理学探讨中药复方治疗奶牛子宫内膜炎的作用机制

【目的】 通过网络药理学对丹参、益母草、黄芩、连翘组成的中药复方进行分析,研究其有效成分治疗奶牛子宫内膜炎的潜在作用靶点,并对靶点作用通路的机制进行阐述。【方法】 利用TCMSP数据库筛选药物成分作用靶点,通过NCBI、GeneCard、geneMap、TTD、DrugBank查找奶牛子宫内膜炎的相关靶点,筛选出药物成分靶点与奶牛子宫内膜炎相关靶点的共有基因靶点,作为该中药复方治疗奶牛子宫内膜炎的预测靶点,并上传到STRING数据库建立蛋白互作(PPI)网络,通过Cytoscape 3.8.2软件根据连接度对PPI网络进行筛选,找到其核心靶点。运用Metascape数据库对核心靶点进行GO功能与KEGG通路富集分析。【结果】 从该中药复方中筛出有效活性成分133种,主要包括槲皮素、山奈酚、黄芩素、丹参酮ⅡA等,通过药物成分找到对应靶点蛋白292个,通过数据库找到奶牛子宫内膜炎的相关靶点130个,筛出中药复方治疗奶牛子宫内膜炎的预测靶点24个,其中核心靶点7个,包括肿瘤坏死因子、蛋白激酶、前列腺素内过氧化物合酶2等。GO功能富集分析得到生物过程20个条目、分子功能6个条目及细胞组分6个条目,生物过程包括脂多糖的反应、白细胞-细胞黏附的正向调节、对无机物的反应等;分子功能包括信号受体活性调节、转录辅激活子的结合、血红素结合等;细胞组分包括细胞膜筏、薄膜侧面、颗粒分泌腔等。KEGG通路富集分析涉及20个基因,参与调控的通路有9条,其中涉及基因较多的包括AGE-RAGE信号通路、癌症蛋白聚糖通路、血流剪切应力与动脉粥样硬化通路及Th17细胞分化通路。【结论】 该中药复方可能是通过调控肿瘤坏死因子、蛋白激酶、前列腺素内过氧化物合酶2等靶点,通过参与AGE-RAGE信号通路及Th17细胞的分化对奶牛子宫内膜炎产生治疗作用。     

9种中药成分对猪传染性胃肠炎病毒体外增殖的抑制作用

运用MTT法结合细胞病变方法测定黄芩苷、穿心莲内酯、大黄素、大黄酸、芦荟大黄素、大黄素甲醚、苦参碱、氧化苦参碱和苦马豆素9种中药成分对猪传染性胃肠炎病毒(TGEV)在ST细胞上增殖的抑制作用,实时荧光定量PCR(Real-time PCR)进一步检测黄芩苷对TGEV在ST细胞上增殖的抑制作用。结果显示,9种中药成分在体外对TGEV在ST细胞上的增殖均有一定的抑制作用,其中黄芩苷对TGEV的生物合成、吸附保护和直接灭活作用的抑制率分别为58.23%、88.12%和100.00%;Real-time PCR检测黄芩苷3种给药方式均能在转录水平显著降低TGEV mRNA的相对表达量,与病毒对照组相比差异极显著(P0.01)。结果表明,9种中药成分在体外对TGEV在ST细胞上的增殖均有一定的抑制作用,以黄芩苷作用最好。     

畜牧兽医执法办案应注意的问题之我见

结合畜牧兽医执法工作实践,总结了10项执法工作中经常遇到的问题,并有针对性的提出了处理建议,以便为国内畜牧兽医执法人员正确执法办案提供参考。     

Long-Term Follow-up of Superficial Digital Flexor Tendonitis Treated by a Single Intralesional Injection of a ReGeneraTing Agent in 51 Horses

ReGeneraTing Agents (RGTA) are nanopolysaccharides engineered to mimic heparan sulfates and have been shown to stimulate tissue repair and healing (skin, cornea, gingival, and muscle) in several animal models of injury and in human medicine. A preliminary study, monocentric and uncontrolled, was conducted to evaluate the efficacy of a dedicated RGTA (named Equitend) in improving the healing quality of the injured tendon after a single and ultrasound-guided intralesional injection. Improvement of ultrasonographic appearance of tendinous or ligamentous lesion was documented at least over 4 months in Equitend-treated horses and was further supported by another study on superficial digital flexor tendonitis, in 51 horses (16 French Standardbred trotters (ST), 13 Thoroughbreds (TB), and 22 eventers). Long-term follow-up of these horses showed high rates of return to racing, with 95% of eventers, 87.5% of French ST, and 77% of TB. The mean duration before the first race or competition was 6.6 and 7.4 months for ST and eventers, respectively. The group of 16 treated ST was then compared with a matched control group, showing that the Equitend-treated group was able to return to a higher level of earning after lesion (74% vs. 15% in the control group). Furthermore, the Equitend-treated group was back in racing 2.4 months earlier than the control group.     

Use of stem cells in equine musculoskeletal disorders

Stem cell therapies for musculoskeletal disorders are becoming commonplace in the horse. In order to decipher the many options available for stem cell therapy and interpret results of accumulating experimental and clinical data, practitioners should have a basic understanding of stem cells.